Our study suggested that DNMBP-AS1 inhibited the progression of colon cancer through the miR-93-5p/17-5p/NHLRC3 axis, which could be potential therapeutic targets for CC. The gene discussed is NHLRC3; the disease is malignant colon neoplasm.